1072009-08-5Relevant articles and documents
THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS
-
Page/Page column 60-61, (2009/05/28)
Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS
-
Referential example 10, (2008/12/08)
The invention provides compounds which are pyrimidines of formula (I) wherein R1 is a group -NR-(CHR)m-X; R2 is a substituted indolyl group; R is H or C1-C6 alkyl; m is 1, 2, 3 or 4; and X is a pyridyl ring; and the pharmaceutically acceptable salts thereof. These compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
PHARMACEUTICAL COMPOUNDS
-
Page/Page column 28; 43, (2008/12/08)
The invention provides a compound which is a pyrimidine of formula (I): The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.